Şunu aradınız:: gadoversetamide (İngilizce - Estonca)

gadoversetamide
gadoversetamiid

optimark gadoversetamide
optimark gadoversetamiid

gadoversetamide is dialysable.
gadoversetamiid on dialüüsitav.

the active substance is gadoversetamide.
toimeaine on gadoversetamiid.

 the active substance is gadoversetamide.
mida optimark sisaldab  toimeaine on gadoversetamiid.

each 10 ml vial contains 3309 mg gadoversetamide.
iga 10 ml viaal sisaldab 3309 mg gadoversetamiidi.

each 20 ml syringe contains 6618 mg gadoversetamide.
iga 20 ml süstel sisaldab 6618 mg gadoversetamiidi.

gadoversetamide does not undergo protein binding in vitro.
gadoversetamiidi seostumist valkudega in vitro ei toimu.

dialysis can be used to remove gadoversetamide from the blood.
gadoversetamiidi eemaldamiseks verest võib kasutada dialüüsi.

it is unknown whether gadoversetamide is excreted in human milk.
ei ole teada, kas gadoversetamiid eritub rinnapiima.

optimark 500 micromol/ml solution for injection in vial gadoversetamide
optimark 500 mikromooli/ml süstelahus viaalis gadoversetamiid

1 ml contains 330.9 mg gadoversetamide, equivalent to 500 micromol.
1 ml sisaldab 330,9 mg gadoversetamiidi, mis on ekvivalentne 500 mikromooliga.

each 10 ml syringe contains 3309 mg gadoversetamide equivalent to 5 millimol.
iga 10 ml süstel sisaldab 3309 mg gadoversetamiidi, mis on ekvivalentne 5 millimooliga.

the pharmacokinetics of gadoversetamide conforms to a two compartment open-model.
gadoversetamiidi farmakokineetika järgib kahe ruumi avatud mudelit.

optimark is a solution for injection that contains the active substance gadoversetamide.
optimark on süstelahus, mis sisaldab toimeainena gadoversetamiidi.

distribution the pharmacokinetics of gadoversetamide conforms to a two compartment open-model.
jaotumine gadoversetamiidi farmakokineetika järgib kahe ruumi avatud mudelit.

the degree of excretion of gadoversetamide in breast milk has not been studied in humans.
13 gadoversetamiidi eritumisastet rinnapiima ei ole inimestel uuritud.

however, the administration of gadoversetamide does not cause a true decrease in serum calcium.
sellele vaatamata ei põhjusta gadoversetamiidi manustamine seerumi kaltsiumisisalduse tegelikku langust.

optimark 500 micromol/ ml solution for injection in a pre-filled syringe gadoversetamide
optimark 500 mikromooli/ ml süstelahus süstelis gadoversetamiid

in the presence of gadoversetamide, the ocp technique produces an erroneous, low value for plasma calcium.
gadoversetamiidi olemasolul annab ocp-meetod plasma kaltsiumi mõõtmisel väära (madala) tulemuse.